Texas HB 46 quietly turned the Compassionate Use Program into something almost medical

In a state where adult-use cannabis remains a third-degree felony at five pounds, the 2025 Texas Legislature did something it rarely does: it expanded medical cannabis access without anyone making a fuss about it.

House Bill 46, signed into law in the 2025 regular session, added three categories of qualifying conditions to the Texas Compassionate Use Program (chronic pain, Crohn's disease, and traumatic brain injury) and authorized three new product forms patients can purchase: transdermal patches, topical lotions, and vaporization. By the program's own historic standards, it is the largest single-bill expansion since the Compassionate Use Program was created in 2015.

It is also, depending on how you measure these things, the first time Texas has had something resembling a real medical-cannabis program.

What the Compassionate Use Program was, and wasn't

Texas legalized "low-THC cannabis" in 2015 via Senate Bill 339, but the original program was barely a program at all. It covered exactly one condition (intractable epilepsy) and capped THC at 0.5% by weight, a threshold so restrictive that it functionally excluded most cannabis-derived medicines. The product was sold as oil. There were no dispensaries open in the first 18 months because no operator wanted to invest in a market with a single qualifying condition and a punitive THC ceiling.

Each subsequent legislative session widened the program by inches.

• HB 3703 (2019) added autism, multiple sclerosis, ALS, terminal cancer, seizure disorders, and incurable neurodegenerative diseases.
• HB 1535 (2021) raised the THC cap from 0.5% to 1% and added PTSD plus all cancer types.
• HB 46 (2025) added chronic pain, Crohn's disease, and TBI; and broke from the "oil only" mold by authorizing patches, lotions, and vaporized products.

The 1% THC cap remains. The dispensary count remains three. There is still no smokable flower, no home cultivation, no reciprocity for out-of-state cards, and no insurance coverage. By the standard of states like New York, New Jersey, or Florida, Texas does not have a "medical cannabis program." But by the standard of Texas in 2015, it has built a system in twenty unanimous-consent-style legislative steps.

Why chronic pain matters

Chronic pain is the single most-cited qualifying condition in every state that allows it as a standalone diagnosis. In 38 of the 41 states with any medical cannabis law (NCSL count), some variant of chronic, intractable, or severe pain qualifies a patient for the registry. The condition's clinical breadth (including back pain, neuropathy, fibromyalgia, and post-surgical pain) makes it the dominant gateway into medical-cannabis programs nationally.

Adding chronic pain to TCUP is a structural change. Until HB 46, a patient with debilitating back pain in Texas had no path into the program; their only legal recourse was opioid prescription or out-of-state travel. Under HB 46, the same patient can, in principle, obtain a Compassionate Use prescription. Though the 1% THC cap means the products available will be lower-potency than what is dispensed in any neighboring legalized state.

The Crohn's and TBI additions follow a similar logic: both have established cannabinoid-treatment evidence bases (TBI especially in the post-2020 VA research literature), and both create legal pathways for populations that were quietly buying out-of-state.

Vaping in a state that just banned smokable hemp

The product-form expansion is the more politically interesting half of HB 46. Until 2025, the Compassionate Use Program was effectively a tincture-and-capsule program. Bioavailability low, onset slow, dosing imprecise. The new authorization of vaporization for prescribed products gives patients a delivery method that mimics the pharmacokinetics of smokable flower (within minutes to peak effect) while remaining technically "non-smokable" under the statute.

This authorization sits awkwardly alongside Texas's March 2026 hemp-products rollback, which banned smokable hemp products including flower and pre-rolled joints, and recalculated THC limits to include THCA compounds. A temporary court injunction (April 8, 2026) lifted the smokable hemp ban pending litigation, but the regulatory signal is clear: Texas is willing to authorize vaporized cannabis through the medical channel while clamping down on hemp-derived alternatives that have served as a de facto adult-use substitute since 2019.

The reading from inside the cannabis-policy community is that HB 46 represents a deliberate consolidation: pull the legitimate medical market into a regulated pipeline, push the unregulated hemp / Delta-8 market out. Whether that consolidation holds depends on the appellate fate of the hemp injunction and the 2027 legislative session.

What HB 46 does not do

It does not legalize adult-use. It does not raise the THC cap above 1%. It does not authorize home cultivation. It does not authorize smokable flower. It does not provide patient-employment protections. It does not provide reciprocity for out-of-state medical cards. And it leaves the three-license dispensary structure intact. Meaning patient access is still bottlenecked through a small, vertically integrated operator base.

For Texans who already qualified under the previous list (patients with epilepsy, cancer, autism, MS, ALS, PTSD, Parkinson's, Alzheimer's) HB 46 changes very little. For the broader population of Texans with chronic pain, Crohn's disease, or TBI, it opens a door that was previously closed.

The door leads into a Texas-shaped room: small, regulated, and unmistakably austere. But it is a door, and that is more than the program had in 2024.